• news.cision.com/
  • OssDsign AB/
  • OssDsign steps up ambition to generate further clinical evidence for its bone replacement products through key recruitment

OssDsign steps up ambition to generate further clinical evidence for its bone replacement products through key recruitment

Report this content

Uppsala, February 7, 2022. OssDsign AB (publ.) today announces that Melanie Marshall has been recruited to a new position as Vice President Clinical & Medical Affairs. This is an important step in the strategic ambition to accelerate data collection and publication of clinical evidence for the company’s innovative bone replacement products, OssDsign Cranial PSI and OssDsign Catalyst. Melanie Marshall has a wealth of experience from senior positions at global medtech companies, such as Boston Scientific, Apatech/Baxter and Medtronic.

The creation of a new senior position with responsibility for Clinical & Medical Affairs is a key component in OssDsign’s strategy to generate and publish further clinical data supporting the global commercialization of its next generation bone replacement products in the treatment of patients with skeletal defects.  


Melanie Marshall is a U.S. citizen, residing in the U.K. She has extensive experience from clinical strategy and execution of clinical trials including both post and pre-market studies. She brings a well-established network among key opinion leaders. Her global experience across U.S., EU, and Australia combined with her in-depth knowledge of spine and bone grafts will be of particular value in the continued roll-out of OssDsign Catalyst in the global medical community.


“We are excited to welcome Melanie Marshall as our new VP Clinical & Medical Affairs and are very pleased to be able to attract someone of her caliber. Her broad experience from the medtech industry and in-depth expertise in the orthopedic field will be of immense value in delivering on our strategic goal to add further clinical evidence for our innovative bone replacement products, not least pertaining to OssDsign Catalyst," comments Morten Henneveld, CEO of OssDsign.


Melanie Marshall will take on her new position on 1 March 2022. She will join as a member of the executive management team and report directly to the CEO.

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign:

OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.



Documents & Links